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Abstract
Objective:  congenital  adrenal  hyperplasia  (CAH)  newborn  screening  can  prevent  neonatal  mor-
tality in  children  with  the  salt-wasting  form  of  the  disease  and  prevent  incorrect  gender
assignments,  which  can  occur  in  females.  However,  the  occurrence  of  false-positive  results
in  preterm  or  low-birth-weight  newborns  creates  some  diagnostic  difﬁculties,  with  consequent
therapeutic  implications.  This  study  aimed  to  report  the  results  of  a  pilot  project  for  neonatal
CAH  screening  conducted  in  the  state  of  Minas  Gerais,  Brazil  from  09/2007  to  05/2008  with  a
three-year  follow-up.
Methods: dried  blood  specimens  were  collected  on  ﬁlter  paper  cards  three  to  seven  days  after
birth of  all  newborns  in  the  period.  Samples  were  analyzed  for  17-hydroxyprogesterone  using
an  enzyme-linked  immunosorbent  assay  (ELISA).
Results:  a  total  of  159,415  children  were  screened.  The  apparent  incidence  of  the  classic  vari-
ant of  the  disease  was  1:9,963,  based  on  initial  diagnoses  following  newborn  screening.  During
the  follow-up  period,  eight  of  16  children  initially  diagnosed  with  CAH  were  reclassiﬁed  as
unaffected,  resulting  in  a  revised  incidence  of  1:19,927.  The  false-positive  rate  was  0.31%,
and  the  positive  predictive  value  was  2.1%.  Sensitivity  and  speciﬁcity  were  100%  and  99.7%,
respectively.
Conclusions:  newborn  screening  is  an  important  public  health  policy  in  developing  countries
such as  Brazil,  where  CAH  remains  underdiagnosed.  It  has  great  potential  to  identify  children
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with  the  disease  who  otherwise  cannot  be  diagnosed  earlier.  Long-term  follow-up  and  monitor-
ing  of  all  children  with  positive  screening  results  are  crucial  to  ensure  a  correct  diagnosis  and
to  calculate  a  reliable  incidence  ratio  of  the  disease.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Um  acompanhamento  de  três  anos  da  triagem  neonatal  para  hiperplasia  adrenal
congênita
Resumo
Objetivo:  a  triagem  neonatal  para  hiperplasia  adrenal  congênita  (HAC)  pode  evitar  a  morte
de recém-nascidos  com  a  forma  perdedora  de  sal  e  o  registro  civil  incorreto  das  meninas.
Entretanto,  a  ocorrência  de  resultados  falso-positivos  em  recém-nascidos  pré-termos  ou  com
baixo  peso  ao  nascer  gera  diﬁculdades  diagnósticas,  com  consequentes  implicac¸ões  terapêuti-
cas.  O  objetivo  do  estudo  foi  avaliar  os  resultados  do  projeto  piloto  de  triagem  neonatal  para
HAC  realizado  no  estado  de  Minas  Gerais,  Brasil,  de  setembro  de  2007  a  maio  de  2008  com
acompanhamento  de  três  anos.
Métodos:  A  dosagem  da  17-hidroxiprogesterona  foi  realizada  por  ensaio  imunoenzimático
(ELISA), em  amostras  de  sangue  seco  coletadas  em  papel-ﬁltro,  três  a  sete  dias  após  o  nasci-
mento de  todos  os  recém-nascidos  no  período.
Resultados:  Foram  triadas  159.415  crianc¸as.  Observou-se  incidência  de  1:9.963  para  a  forma
clássica da  doenc¸a,  baseando-se  nos  diagnósticos  iniciais.  Durante  o  período  de  acompan-
hamento, 8  de  16  crianc¸as  inicialmente  diagnosticadas  com  HAC  foram  reclassiﬁcadas  como
não  afetadas,  resultando  em  uma  incidência  corrigida  de  1:19.927.  A  taxa  de  falsos  positivos
foi  de  0,31%,  e  o  valor  preditivo  positivo  foi  de  2,1%.  A  sensibilidade  e  a  especiﬁcidade  foram
100%  e  99,7%,  respectivamente.
Conclusões: a  triagem  neonatal  é  uma  importante  política  de  saúde  pública  para  países  em
desenvolvimento como  o  Brasil,  onde  a  HAC  continua  subdiagnosticada.  Ela  possui  grande  poten-
cial  para  identiﬁcar  crianc¸as  que  poderiam  não  ter  a  doenc¸a reconhecida  precocemente.  O
acompanhamento  em  longo  prazo  e  o  monitoramento  de  todas  as  crianc¸as  com  resultados  posi-
tivos  na  triagem  são  cruciais  para  conﬁrmac¸ão  diagnóstica  e  para  o  correto  cálculo  da  incidência
da  doenc¸a.
© 2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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ste é Introduction
Congenital  adrenal  hyperplasia  (CAH)  consists  of  a  group  of
inborn autosomal  recessive  disorders  that  are  characterized
by the  deﬁciency  of  one  of  the  enzymes  involved  in  corti-
sol synthesis  in  the  adrenal  cortex.  Over  90%  of  CAH  cases
are due  to  21-hydroxylase  deﬁciency  (21-OHD),  which  is  one
of the  most  common  inborn  errors  of  metabolism,  with  a
variable incidence  according  to  ethnicity  and  geography.1--3
The  global  incidence  of  the  classic  form  of  CAH  is
1:15,000 live  births,  as  determined  by  screening  programs.
Frequencies varying  from  1:10,000  to  1:14,000  have  been
observed in  Europe.  In  North  America,  the  incidence  varies
from 1:15,000  to  1:16,000.  The  reported  rates  of  CAH
have been  as  high  as  1:280  among  the  Yupik  people  of
Alaska and  1:2,100  on  the  French  island  of  Réunion  in  the
Indian Ocean;  both  of  these  populations  are  geographically
isolated.4 The  reported  incidence  of  CAH  in  the  two  Brazil-
ian states  that  have  routinely  included  CAH  in  their  public
newborn screening  programs  is  1:11,655  in  the  South  (Santa
Catarina) and  1:10,325  in  the  Midwest  (Goiás).5,6
Newborn  screening  for  CAH,  which  is  now  performed
Ein many  countries,  has  reduced  the  number  of  deaths  by
enabling earlier  diagnosis.1 In  females,  the  classic  form
of the  disease  can  be  diagnosed  through  the  detection  of
ambiguous genitalia  (AG)  at  birth.  In  males,  however,  the
(
t
Bbsence  of  overt  physical  signs  at  birth  can  lead  to  avoidable
eaths caused  by  salt-losing  crises.
The  main  goals  of  screening  are  to  detect  the  severe,
alt-wasting (SW)  form  of  the  disease;  to  prevent  shock,
rain damage  or  death,  by  implementing  pre-symptomatic
reatment; and  to  prevent  or  shorten  the  period  of  incorrect
ender assignment  that  can  occur  in  females.7,8 However,
he occurrence  of  false-positive  results  in  sick  children,
reterm or  low  birth  weight  newborns  creates  some  diagnos-
ic difﬁculties,  with  consequent  therapeutic  implications.9
ewborn  screening  for  CAH  also  provides  knowledge  of  the
eal incidence  of  the  disease  in  the  population.
The  objective  of  this  study  was  to  provide  the  results  of
 pilot  project  for  neonatal  CAH  screening  developed  in  the
tate of  Minas  Gerais  (MG),  Brazil,  aimed  at  establishing  a
outine program.
ethods
he  pilot  project  for  neonatal  CAH  screening  was  included  in
he newborn  screening  program  of  the  State  of  Minas  Gerais
um artigo Open Access sob a licença de CC BY-NC-NDPTN-MG) from  September  of  2007  to  May  of  2008.
This  study  was  approved  by  the  Research  Ethics  Commit-
ee of  the  Universidade  Federal  de  Minas  Gerais  (UFMG),
razil (ETIC  392/07)  and  by  the  Minas  Gerais  State  Health
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epartment.  The  study  includes  only  data  of  children  whose
egal guardian  provided  written,  informed  consent.  The
TN-MG has  been  implemented  by  the  state  health  adminis-
ration in  partnership  with  the  Center  for  Newborn  Screening
nd Genetic  Diagnostics  (Núcleo  de  Ac¸ões  e Pesquisa  em
poio Diagnóstico  -  NUPAD),  UFMG,  since  September  of
993. The  PTN-MG  covers  all  municipalities  in  the  state,
nd routinely  screens  for  four  diseases:  congenital  hypothy-
oidism, phenylketonuria,  cystic  ﬁbrosis,  and  sickle  cell
isease. The  newborn  screening  program  in  Minas  Gerais  fol-
ows  the  Brazilian  public  health  recommendations,  which
im to  achieve  100%  population  coverage  and  deﬁne  the
ewborn screening  process  in  ﬁve  steps:  laboratory  testing,
ctive surveillance  of  suspected  cases,  diagnostic  conﬁrma-
ion, treatment,  and  follow-up  by  a  multidisciplinary  team.
lthough recommended,  universal  newborn  testing  has  not
et  been  fully  implemented  in  many  Brazilian  states,  due
n part  to  ﬁnancial  inequality  and  Brazil’s  large  territory.
inas Gerais  is  one  of  the  largest  Brazilian  states,  with  853
unicipalities and  approximately  19,600,000  inhabitants
according to  the  2010  census  by  the  Instituto  Brasileiro  de
eograﬁa e  Estatística  [IBGE]).
A  strict  protocol  is  routinely  followed  to  ensure  reliable
esults. Whole  blood  is  drawn  via  a  heel  prick  and  dried  on
lter paper  cards  (S&S  903®)  three  to  seven  days  after  birth.
ried blood  spot  specimens  are  obtained  in  health  care
enters (or  in  hospitals  for  preterm  or  sick  newborns)  and
hen mailed  to  NUPAD,  where  they  are  processed.  A  positive
esult triggers  an  immediate  outreach  process.  The  NUPAD
eam makes  telephone  contact  with  the  health  care  center
or hospital),  in  order  to  either  get  a  new  sample  collected
r to  refer  the  child  to  medical  consultation,  according  to
he speciﬁc  protocol  for  each  disease  and  the  degree  of
lteration of  the  result.
Blood  samples  are  processed  and  analyzed  at  NUPAD’s
aboratory, and  the  results  are  delivered  to  the  health  care
enters (or  hospitals)  as  quickly  as  possible.  There  are
pproximately 20,000  births  monthly  in  Minas  Gerais,  and
early the  same  number  of  newborns  are  screened  through
he aforementioned  public  program.  The  current  population
overage of  the  program  is  98%.
Newborn  screening  for  CAH  was  implemented  as  part
f a  research  study  to  prepare  the  state  for  an  expan-
ion in  its  program,  which  is  expected  to  include  this
isease in  the  routine  panel.  It  was  performed  by  measuring
7-hydroxyprogesterone  (17-OHP)  levels  using  the  sample
solated from  dried  blood  spot  specimens  for  the  routine
creening by  PTN-MG.  The  17-OHP  levels  were  measured
sing the  Umelisa  17-OH  Progesterona  Neonatal  (Havana,
uba) assay  with  a  reference  value  (RV)  of  80  nmol/L
conversion factor:  1  nmol/L  of  blood  =  0.73  ng/mL  of  serum)
or normal  weight  (≥  2,500  g)  and  full  term  infants  (≥  37
eeks of  gestation).  A  ﬂow  diagram  based  on  established
rotocols in  literature  was  proposed,  and  the  cut-offs  80
mol/L and  160  nmol/L  were  adopted  for  deﬁning  the  pro-
edures. (Fig.  1).
Following the  preliminary  data  analysis,  a  speciﬁc  17-
HP cut-off  value  was  determined  for  preterm  infants  (<  37
eeks of  gestation)  and  children  with  birth  weights  below
,500 g,  based  on  the  99th percentiles  of  the  results  ana-
yzed. All  samples  with  17-OHP  values  below  160  nmol/L
ere considered  to  be  normal.
g
b
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All  children  who  met  the  criteria  and  needed  a  follow-up
ere referred  to  pediatric  endocrinologists  at  the  outpa-
ient clinic  of  the  University  Hospital,  where  they  were
linically evaluated.  Conﬁrmatory  serum  tests  for  17-OHP,
ndrostenedione, testosterone,  sodium  (Na+),  and  potas-
ium (K+) were  conducted  for  all  children  at  their  ﬁrst
isit to  the  endocrinologist.  Serum  17-OHP  was  measured
sing radioimmunoassay  (RV  <  204  ng/dL).  Androstenedione
RV <  1.6  ng/mL)  and  testosterone  (RV  =  male  term:  0.75-4.0
g/mL; female  term:  0.20-0.64  ng/mL;  male  preterm:  0.37-
.98 ng/mL;  and  female  preterm:  0.05-0.22  ng/mL)  were
easured using  chemiluminescence.
Children  who  presented  clinical  evidence  of  salt  loss
weight loss  or  insufﬁcient  weight  gain  and/or  dehydration
igns), and  females  with  signs  of  virilization  (Prader  stages
-V) plus  increased  serum  hormones  (17-OHP,  androstene-
ione, and  testosterone),  low  Na+ levels  (<  135  mmol/L),
nd high  K+ levels  (>  5.5  mmol/L)  were  assigned  a  CAH  diag-
osis. They  were  treated  with  steroids:  10  to  15  mg/m2 of
ydrocortisone acetate  and  0.1  to  0.2  mg  of  ﬂudrocortisone,
aily.
Diagnoses were  deemed  as  inconclusive  when  the  results
f the  conﬁrmatory  serum  hormones  were  altered,  but  the
on levels  were  normal  and  clinical  signs  were  absent.  Chil-
ren who  were  diagnosed  with  CAH  or  who  had  inconclusive
iagnoses were  followed-up  in  regular  clinical  consulta-
ions, and  had  laboratory  measurements  of  their  17-OHP
nd androstenedione  levels.  Inconclusive  cases  were  moni-
ored until  the  children’s  17-OHP  levels  normalized.  At  that
oint, these  cases  were  classiﬁed  as  false  positives,  and  the
hildren were  discharged  from  the  program.
Data  were  obtained  from  the  screening  records  and  ana-
yzed using  Microsoft®  SQL  ServerTM 2000  (Washington,  EUA)
oftware. To  calculate  the  incidence  of  CAH,  the  number  of
AH cases  conﬁrmed  by  three  years  of  follow-up  visits  was
ivided by  the  number  of  screened  children.  Positive  predic-
ive value  (PPV),  sensitivity,  and  speciﬁcity  were  calculated.
esults
rom  September  of  2007  to  May  of  2008,  159,415  children
ere screened  for  CAH  in  Minas  Gerais,  which  corresponds
o almost  all  the  children  born  in  the  state  during  this
eriod. Children  had  a  median  age  of  6  days  at  screening
mean =  8  ±  14  days).
During this  period,  16  children  were  assigned  a  diagno-
is and  began  treatment  for  CAH,  and  the  incidence  of  the
lassic form  of  the  disease  was  determined  to  be  1:9,963
ased on  the  initial  diagnoses.  However,  after  three  years
f follow-up  visits,  only  eight  of  these  children  (three  SW
ales) were  conﬁrmed  to  have  CAH,  and  maintained  under
ontinued treatment.  The  other  eight  children  received
lucocorticoid treatment  during  the  ﬁrst  year  of  life  (subse-
uently discontinued),  and  a  diagnosis  of  CAH  was  discarded
ollowing clinical  evaluations  and  normal  17-OHP  serum  lev-
ls  after  withdrawal  of  medication.  These  children  exhibited
igh 17-OHP  levels  and  at  least  one  clinical  sign  that  sug-
ested CAH  (insufﬁcient  weight  gain,  mild  hyponatremia,  or
oth) at  their  ﬁrst  visit.  During  the  follow-up,  a  complete
ormalization of  17-OHP  was  achieved  without  periodic
djustments of  the  hydrocortisone  dosage.  They  remained
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17-OHP on first filter paper sample
<80 nmol/L 80-160  nmol/L >160 nmol/L
Normal
Low risk of 
CAH
Second filter paper sample
<80 nmol/L >80 nmol/L
High risk of 
CAH
Immediate referral 
to an 
endocrinologist
Clinical evaluation and 
confirmatory serum tests
Normal clinical evaluation 
and normal confirmatory 
serum tests
Normal clinical evaluation, 
normal ion levels, and
elevated serum hormones
Suggestive clinical evaluationa
 or
altered ion levelsb and elevated 
serum hormones
CAH
Treatment and 
follow-up with
regular clinical 
consultations and
laboratory 
measurements
Inconclusive
Follow-up with 
regular clinical 
consultations and
laboratory 
measurements
False-positives
Normalization of 
serum hormones 
Rising serum 
hormones
Fig.  1  PTN-MG  neonatal  congenital  adrenal  hyperplasia  (CAH)  screening  ﬂowchart.
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ha virilization  in  girls  or  evidence  of  salt  loss  in  either  gender.
b hyponatremia  and  hyperkalemia.
asymptomatic  after  withdrawing  medication,  and  were  con-
sidered false  positives.
Therefore, based  on  the  ﬁnal  results  of  this  pilot  project,
the incidence  of  the  classic  form  of  CAH  in  Minas  Gerais,
Brazil was  determined  to  be  1:19,927,  with  a  male-to-
female ratio  of  1:1.6.  Table  1  summarizes  the  characteristics
of the  eight  affected  children.
All  the  children  with  CAH  were  considered  at  high  risk
upon screening,  and  were  immediately  referred  for  medi-
cal evaluation.  The  median  17-OHP  value  of  the  ﬁlter  paper
blood samples  from  the  children  who  were  ultimately  con-
ﬁrmed to  have  CAH  was  250  nmol/L  (196-660  nmol/L).
ﬁ
t
wFrom the  eight  children  diagnosed  with  CAH,  six  (75%)
ad the  salt-wasting  form,  and  two  had  the  simple  virilizing
orm. All  ﬁve  female  newborn  exhibited  clinical  signs  of  AG
t birth  (Prader  stages  I-IV)  that  suggested  a  diagnosis  before
he release  of  the  screening  results.  One  female  (Prader  I
enitalia)  and  all  three  male  children  were  diagnosed  pri-
arily via  neonatal  screening.  None  of  the  affected  females
ad incorrect  gender  assignment.  Consanguinity  was  identi-
ed among  the  parents  of  Cases  3  and  7;  however,  none  of
he children  had  a  positive  family  history  of  CAH.
The  average  age  at  screening  of  the  children  diagnosed
ith CAH  was  7  ±  2  days.  The  median  age  at  diagnosis  (and  at
304
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Table  1  Clinical  and  laboratory  ﬁndings  of  children  with  congenital  adrenal  hyperplasia  diagnosed  by  the  neonatal  screening  project.
Case  Gender  GA  (wk)  BW  (g)  Clinical
form/Pradera
Age at
screening
(days)
Age  at
treat-
ment
(days)
Clinical
suspicion
17-OHP
ﬁlter  paper
(nmol/L)
17-OHP
serum
(ng/dL)
Andro-
stenedione
(ng/mL)
Testoster-one
(ng/mL)
Na+  K+
1  F  41  3,620  SW/III  6  14  Yes  250  2,270  31  -  125  6.3
2 F  39  3,390  SW/III  7  23  Yes  660  3,630  0.3  6.0  120  7.1
3 F  37  2,515  SW/IV  5  13  Yes  660  3,680  0.3  0.3  131  5.9
4 F  38  2,900  SV/II  5  45  Yes  214.46  2,790  51  1.5  135  5.5
5 F  36  2,500  SV/I  6  581  No  196.17  4,180  38  -  133  5.9
6 M  39  3,900  SW  9  45  No  250  2,690  5.7  1.0  135  7.6
7 M  40  4,000  SW  9  81  No  213.43  2,880  32  1.2  129  7.9
8 M  40  3,380  SW  8  32  No  660  2,160  310  5.5  121  -
BW, birth weight; F, female; GA (wk), gestational age in weeks; K+, potassium; M, male; Na+, sodium; SV, simple virilizing; SW, salt-wasting; 17-OHP, 17-hydroxyprogesterone
*  stages of genital virilization
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the  beginning  of  treatment)  was  39  days  (13-581  days).  The
diagnosis of  the  simple  virilizing  form  of  CAH  was  delayed
for one  female  child,  who  was  born  prematurely  (Case  5)
with a  Prader  I  genitalia.  She  was  evaluated  at  49  days  of
age; however,  no  treatment  was  initiated  until  the  age  of  19
months, when  the  diagnosis  was  conﬁrmed.
The  median  serum  17-OHP  level  (RV  <  204  ng/dL)  was
high: 2,835  ng/dL  (2,160-4,180  ng/dL).  The  17-OHP  levels
of the  children  with  the  salt-wasting  form  did  not  dif-
fer from  those  of  the  children  with  the  simple  virilizing
form (p  =  0.43).  The  median  serum  androstenedione  levels
(RV <  1.6  ng/mL)  were  very  high:  32  ng/mL  (0.3-310  ng/mL).
The serum  testosterone  levels  were  high,  and  did  not  dif-
fer between  male  and  female  children  (p  =  0.83).  The  Na+
and  K+ levels  in  the  children  with  the  salt-wasting  form  of
CAH were  in  the  abnormal  range:  127  ±  6  mmol/L  (RV  =  135-
145 mmol/L)  and  7.0  ±  0.8  mmol/L  (RV  =  3.5-5.5  mmol/L),
respectively, at  diagnosis.
The false-positive  rate  and  the  PPV  were  calculated  for
the ﬁrst  six  months  of  the  project.  During  this  period,
106,476 children  were  screened  for  CAH,  and  328  cases
were determined  to  be  false  positives  after  screening  and
follow-up visits.  No  false-negative  cases  were  identiﬁed  dur-
ing the  ﬁrst  three  years  of  follow-up,  but  active  search
was not  performed.  Therefore,  the  false-positive  rate  was
0.31%, and  the  PPV  was  2.1%.  Sensitivity  and  speciﬁcity
were 100%  and  99.7%,  respectively.  Of  the  315  children  with
false-positive diagnoses  who  were  monitored  by  the  PTN-
MG, 63%  were  either  born  prematurely,  had  a  low  birth
weight, or  experienced  both  conditions.  The  false-positive
cases were  followed-up  for  a  median  of  17  months  after
birth (2.6-34  months)  until  their  17-OHP  levels  normal-
ized.
Discussion
An  incidence  ratio  of  1:19,927  was  calculated  for  the  clas-
sic form  of  CAH  in  Minas  Gerais,  following  the  screening
pilot project.  This  incidence  was  lower  than  that  of  the
other Brazilian  states  where  CAH  screening  has  been  per-
formed: 1:7,500  and  1:13,809  in  the  South  and  1:10,325  in
the Midwest.5
Goiás  (in  Midwestern  Brazil)  was  the  ﬁrst  Brazilian  state
to include  CAH  in  its  public  program  of  newborn  screening,
which was  implemented  in  1997  and  is  now  widely  estab-
lished. An  incidence  ratio  of  1:10,325  was  reported  for  the
classic form  of  CAH  in  the  state,  after  follow-up  of  an  aver-
age of  16  months.5
Another  Brazilian  state  that  has  routinely  included  CAH
in its  public  program  of  screening  since  2000  is  Santa  Cata-
rina (in  Southern  Brazil),  with  a  reported  incidence  ratio  of
1:11.655 among  378.337  newborns.6
The  incidence  of  CAH  in  another  Southern  state  (1:7,500)
was reported  as  one  of  the  highest  in  the  world.10 How-
ever, this  number  was  disputed  by  a  recent  study  where
the authors  emphasized  that  those  ﬁgures  were  obtained
through voluntary,  self-paid  tests  with  unconﬁrmed  clinical
outcomes.5
This  large  variation  in  reported  prevalence  might  be  due
to Brazil’s  large  territory  and  diversity,  but  it  might  also  be
due to  methodological  differences  across  the  studies.
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The screening  in  Minas  Gerais  was  performed  over  eight
onths, but  the  clinical  and  laboratory  follow-ups  with  the
hildren who  had  positive  screening  tests  lasted  up  to  34
onths, until  the  diagnosis  was  either  conﬁrmed  or  proven
o be  a  false-positive  result.
One  explanation  for  the  lower  incidence  of  CAH  in  Minas
erais observed  in  the  present  study  compared  with  those
f other  Brazilian  states  may  be  the  lengthy  follow-up
eriod, which  enabled  the  exclusion  of  false  positives.  A
igh incidence  of  1:9,963  was  initially  incorrectly  assessed;
fter the  clinical  and  laboratory  follow-up,  approximately
alf of  the  initial  diagnoses  of  CAH  were  determined  to
e false-positives.  The  children  with  false-positive  diag-
oses exhibited  high  conﬁrmatory  serum  levels  of  17-OHP,
nd at  least  one  clinical  sign  that  suggested  CAH  at  the
eginning of  the  follow-up.  CAH  was  discarded  and  the  chil-
ren remained  asymptomatic  after  withdrawing  medication.
herefore, only  the  conﬁrmed  cases  of  CAH  were  consid-
red in  the  calculation  of  disease  incidence.  This  points  to
ollow-up monitoring  as  an  essential  step  for  a  reliable  CAH
iagnosis.
Difﬁculties with  CAH  diagnoses  are  common9 and  may
ave accounted  for  the  initially  high  apparent  incidence  of
he disease  in  the  present  pilot  study.  Decisions  regarding
reatment should  always  be  postponed  for  asymptomatic
hildren and  for  those  with  only  slightly  elevated  17-OHP
evels.11 Tests  with  higher  speciﬁcities  for  diagnostic  conﬁr-
ation, such  as  a  molecular  genetic  analysis  of  the  CYP21
ene, have  been  suggested  as  a  complementary  analysis  in
uch cases.9,12
The  present  study  was  the  ﬁrst  to  examine  the  incidence
f CAH  in  Minas  Gerais,  a  large  state  in  the  Southeastern
egion of  Brazil,  with  a  territory  of  586,528  km2. The  dis-
ase incidence  herein  reported  is  close  to  those  reported
n Japan  (1:18,000),  New  Zealand  (1:21,270),  and  in  North-
astern Italy  (1:21,380).7,13,14
The  duration  of  this  study  might  be  considered  a  hin-
rance for  drawing  conclusions.  However,  the  incidence
alculated in  this  screening  pilot  project  is  highly  credible,
ue to  the  state-wide  coverage  of  the  PTN-MG  (nearly  100%)
nd to  the  large  number  of  screened  children  despite  the
hort period  of  time  devoted  to  the  pilot.
The  evaluation  of  this  pilot  project  points  to  the  potential
or reducing  CAH  morbidity  and  mortality  rates  among  the
ffected children.
Clinical suspicion  for  CAH  was  low  at  birth:  half  of  the
ases in  the  present  study  were  diagnosed  by  screening
lone. One  female  with  the  simple  virilizing  form  of  the  dis-
ase and  Prader  I  genitalia,  as  well  as  three  male  children
ith the  salt-wasting  form  of  the  disease,  could  not  have
een diagnosed  earlier  without  the  use  of  screening,  and
he males  could  have  died  from  dehydration  and  shock.  It  is
nown that  more  female  than  male  children  are  diagnosed
n the  absence  of  screening  (4:1),  which  indicates  that  there
re unrecognized  deaths  due  to  CAH  in  male  children.15,16
CAH  treatment  onset  was  late  in  this  pilot  study,  mainly
ue to  the  initial  difﬁculties  to  implement  a protocol  for
AH in  the  PTN-MG  without  previous  experience  with  the
anagement of  this  disease  within  the  state  program  of
ewborn screening.  According  to  the  Working  Group  on
eonatal Screening  of  the  European  Society  for  Pediatric
ndocrinology, the  results  of  newborn  screening  for  CAH
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hould  ideally  be  available  within  ten  days  after  birth.17
his  timeline  is  important,  because  delays  in  beginning
reatment raise  concerns  about  the  potential  beneﬁts  of
mplementing screening  programs  for  CAH.  Delayed  diag-
oses may  invalidate  the  primary  goal  of  CAH  screening,  i.e.
o avoid  salt-wasting  crises  and  thereby  reduce  the  morbid-
ty and  mortality  of  the  disease.  Data  from  the  Netherlands
ublished in  2001  showed  that  specimen  collection  is  usu-
lly performed  within  two  days  of  life,  and  all  the  children
ith CAH  diagnosed  via  screening  were  able  to  begin  treat-
ent before  the  tenth  day  of  life,  thus  preventing  severe  salt
oss.18 However,  during  the  pilot  project  at  Minas  Gerais,  it
as possible  to  identify  children  with  the  disease  who  oth-
rwise could  not  be  diagnosed  earlier,  even  with  an  average
ge of  seven  days  at  screening.
Reduced  false-positive  rates  and  improved  PPVs  might  be
btained through  both  optimizing  the  17-OHP  cut-off  points
ccording to  a  higher  number  of  birth  weight  categories  or
estational age,  and  implementing  a  second-tier  test.  These
trategies are  used  in  many  countries19--23 to  offset  the  fact
hat serum  17-OHP  levels  may  take  several  months  to  return
o normal  in  false-positive  cases.  This  time  can  represent
igniﬁcant psychological  stress  for  the  family.
Because  of  the  poor  management  of  CAH  in  developing
ountries, the  authors  believe  that  implementing  a  program
f newborn  screening  for  CAH  is  an  important  public  health
olicy with  conﬁrmed  beneﬁts,  as  herein  reported.  Newborn
creening programs  represent  one  of  the  great  advances  for
he early  care  of  treatable  diseases  in  childhood.24 Based
n the  development  of  this  pilot  program,  it  can  concluded
hat the  implementation  of  a  routine  program  of  newborn
creening for  CAH  would  be  beneﬁcial.  In  addition,  long
erm follow-up  and  monitoring  of  all  children  with  positive
creening results  are  crucial  to  ensure  a  correct  diagnosis
nd to  calculate  a  reliable  incidence  ratio.  Furthermore,  to
void the  occurrence  of  overtreatment,  improved  diagnos-
ic methods  and  follow-up  procedures  should  be  introduced
efore newborn  screening  for  CAH  is  implemented.  Multi-
enter and  long-term  analyses  are  needed  to  evaluate  these
ata appropriately.  The  results  herein  reported  may  help
vercome difﬁculties  in  the  implementation  of  future  pro-
rams.
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